#USA #San Diego #Class Action #Sarepta Therapeutics #ELEVIDYS

Sarepta Therapeutics Under Fire for Alleged Safety Issues in ELEVIDYS Therapy

Sarepta Therapeutics, Inc., a company known for its innovative therapies targeting Duchenne muscular dystrophy, is currently facing a class action lawsuit that serves as a potential turning point for many of its investors. Robbins Geller Rudman & Dowd LLP announced the opportunity for those who acquired Sarepta securities between June 22, 2023, and June 24, 2025, to step forward as lead plaintiffs in the lawsuit, compelled by severe allegations surrounding the company's flagship treatment, ELEVIDYS.

The Details of the Lawsuit

The legal action, titled Dolgicer v. Sarepta Therapeutics, Inc., accuses the company, along with several top executives, of violating the Securities Exchange Act of 1934. The crux of the suit lies in allegations that Sarepta made misleading statements regarding the safety and efficacy of ELEVIDYS, a gene therapy that was expected to revolutionize treatment for Duchenne muscular dystrophy. As stated in the complaint, during the alleged class period, Sarepta failed to disclose significant risks associated with the treatment that raised major concerns among patients and investors alike.

Specifically, the lawsuit claims that:

• - Significant Safety Risks: ELEVIDYS carried substantial safety risks that were not disclosed. Patients faced severe risks that should have been communicated transparently.
• - Flawed Trial Protocols: The clinical trial methodologies employed by Sarepta did not adequately determine the potential for serious side effects, ultimately putting patients at risk.
• - Regulatory Consequences: After adverse events were reported, Sarepta was forced to stop recruitment and dosing in ongoing clinical trials, raising scrutiny from regulatory bodies, which has further complicated their path to receiving expanded approvals.

Events Leading to Investor Loss

On March 18, 2025, Sarepta disclosed that a participant in the ELEVIDYS treatment experienced acute liver failure resulting in death, a shocking revelation that sent the stock plummeting more than 27%. This was just the beginning, as subsequent disclosures revealed more dire outcomes:

• - April 4, 2025: The company revealed that EU regulatory authorities had requested further review of the alarming incidents related to ELEVIDYS, causing the stock to drop another 7%.
• - June 15, 2025: A second death following treatment with ELEVIDYS was reported, leading to the suspension of deliveries and treatment protocols for non-ambulatory patients. This led to an intense sell-off, with stocks plunging over 42%.
• - June 24, 2025: The FDA released a Safety Communication regarding the acute liver failure associated with ELEVIDYS, further driving stock prices down by 8%.

These troubling events have left many investors reeling, prompting them to consider joining the class action lawsuit as they seek restitution for their losses.

The Role of Lead Plaintiffs

Under the Private Securities Litigation Reform Act of 1995, investors who participated in the purchase of Sarepta securities during the specified class period possess the right to take action. Those interested in becoming lead plaintiffs must demonstrate a significant financial interest in the claims and can influence the direction of the class action, choosing the legal representation they see fit.

About Robbins Geller Rudman & Dowd LLP

Robbins Geller Rudman & Dowd LLP is widely recognized as a premier law firm specializing in representing investors embroiled in securities fraud and shareholder litigations. They have consistently ranked as one of the top firms in securing monetary relief for investors, boasting a strong track record of over $2.5 billion recovered in securities class action cases in 2024 alone. Their extensive resources and experience make them a formidable ally for any investors seeking to navigate this complex legal landscape.

As Sarepta Therapeutics responds to these allegations, the investor community awaits critical developments that will impact the future of the company and its treatments. Investors facing losses are encouraged to connect with Robbins Geller and explore their options regarding this unfolding situation. For more detailed information, investors can visit Robbins Geller's website.